BY MARKETWIRE
-
ALK on launch of tablets for children: Waiting lists have ensured a good start
The waiting checklists have actually been longer than ALK had actually anticipated.
-
Zealand Pharma CEO hails “crown jewel” as far more potent than Eli Lilly’s
According to Zealand Chief Executive Officer Adam Steensberg, his excessive weight prospect is 5 to 10 times extra powerful than Eli Lilly’s and has the very same tolerabilit…
-
Novo Nordisk’s price war and executive charm offensive could avert sales decline
Broker agent company Kepler Cheuvreux states Novo Nordisk’s change in tone is totally reasonable.
-
WSA expects low single-digit growth in 2025/26
This appears from the listening devices business’s monetary record on its staggered , which was released on Thursday early morning CET.
-
Novartis expects growth of 5-6% in the medium term
Novartis additionally anticipates sales of the several sclerosis medication Kesimpta, in which Genmab has a risk, to remain to get to peak sales of greater than USD 6 billion.
-
Roche obtains promising trial data with breast cancer tablet
In the study, drug giredestrant has helped women with a form of early breast cancer, allowing them to live longer without the disease progressing.
-
Novo Nordisk lowers prices for self-paying customers and launches introductory offer
Beginning Monday, brand-new consumers can obtain 2 months of Wegovy or Ozempic for USD 199 each month.
-
Lundbeck takes the lead in acquisition race for Irish company
Lundbeck’s competitor for the procurement, Alkermes, currently has the possibility to boost its deal for Irish firm Avadel Pharmaceuticals.
-
Pfizer sells stake in vaccine partner BioNTech
Both business have actually collaborated to create an injection versus COVID-19.
-
Novo Nordisk partner Korro Bio dives after failed study
The research has actually placed the cooperation in between Korro Biography and Novo Nordisk on hold.
